Colorectal Cancer Now a Leading Cause of Cancer Death in Adults Under 50 — New Research, Emerging Insights, and the Debate Over Repurposed Drugs (2026)

By Editorial Team

Colorectal cancer — once considered a disease of older adults — is now the number one cause of cancer-related death in Americans under age 50, according to new research published in the Journal of the American Medical Association (JAMA). This alarming shift marks a major public-health milestone and highlights the urgent need for better awareness, early screening, and research into causes. 


A Dramatic Shift in Cancer Mortality Trends

Until recently, cancers like lung, breast, and leukemia were the top killers for people under 50. But a new analysis of U.S. cancer mortality data from 1990 through 2023 shows that colorectal cancer (CRC) mortality has increased by about 1.1% per year, even as deaths from most major cancers have declined. By 2023, colorectal cancer had risen from the fifth leading cause of cancer death in younger adults to the first. (American Hospital Association)

Key Trend Drivers

  • Decreases in death rates for other cancers (lung, breast, leukemia, brain). 

  • Continued increase in CRC deaths among younger adults. 

  • CRC now surpasses other cancers in overall mortality for people under 50. 

This shift was more rapid than predicted — earlier estimates had projected CRC would become the top cause by 2030 — but it happened years ahead of schedule. (news.cuanschutz.edu)

The Rising Burden of Early-Onset Colorectal Cancer (EO-CRC)

Colorectal cancer diagnosed before age 50 — often termed early-onset CRC — is increasing globally and particularly in high-income countries. Incidence trends from multiple population studies show that:

  • EO-CRC rates have risen in 27 out of 50 countries studied. (PMC)

  • Young adults (20–49) are increasingly affected. (PMC)

  • The rise is driven by rectal and colon cancers. (PMC)

This trend contrasts with declining CRC incidence in adults over 50, most of whom benefit from routine screening programs. (PMC)

What the Advanced Science Wiley Study Adds

A recent mechanobiology study published in Advanced Science (DOI: 10.1002/advs.202514693) adds a biological dimension to the story. Researchers found that early-onset colorectal tumors have unique biomechanical signatures, including:

Understanding these mechanical patterns could help future researchers develop better screening tools and targeted therapies for younger patients, who often present with more advanced disease stages. (advanced.onlinelibrary.wiley.com)

Why Younger Adults Are at Rising Risk

The exact reasons behind this shift remain unclear, but evidence suggests multiple contributors:

Lifestyle & Environmental Factors

Diet, obesity, lack of physical activity, and alcohol use are established CRC risk factors, affecting cell signaling, inflammation, and cancer initiation. (Wikipedia)

Delayed Diagnosis

Many young patients do not get screened until symptoms are severe, often leading to diagnoses at more advanced stages. (Wikipedia)

Microbiome & Genetic Changes

Emerging research suggests that changes in gut microbiota and early life environmental exposures might influence cancer risk — but more studies are needed. (ScienceDaily)

Screening Guidelines

The U.S. Preventive Services Task Force now recommends beginning average-risk screening at age 45, but some experts argue that even earlier screening may be warranted, especially in individuals with symptoms or family history. (news.cuanschutz.edu)

Repurposed Antiparasitic Drugs: What the Case Reports Say

Across blogs and online compilations, there is widespread interest in repurposing antiparasitic medications like fenbendazole, ivermectin, and mebendazole as potential cancer therapies — especially in advanced colorectal cancer. The OneDayMD compilation, for example, describes case reports where patients reported tumor shrinkage or remission while using these drugs alongside conventional therapies. (OneDayMD 2026)

  • Some case narratives describe patients with stage 3 or stage 4 CRC experiencing dramatic tumor reduction after incorporating ivermectin, fenbendazole, and mebendazole alongside chemotherapy or radiation. (OneDayMD)

  • Supporters often highlight in vitro studies suggesting that ivermectin can inhibit cancer cell growth and disrupt the Wnt signaling pathway, which is implicated in CRC progression. (OneDayMD)

  • Fenbendazole and mebendazole are discussed in online circles for potential effects on cancer metabolism and microtubule function, similar in concept to some established anticancer drugs, but they are not FDA-approved cancer treatments. (OneDayMD)

What This Means for Patients and Caregivers

1. Early Detection Matters

The rise in young-age CRC highlights the importance of recognizing symptoms — like changes in bowel habits, blood in the stool, or unexplained weight loss — and consulting a healthcare provider promptly.

2. Evidence-Based Treatment

Standard CRC treatments, supported by clinical trials, remain the backbone of care. Participation in clinical trials can offer access to emerging therapies under scientific oversight.

3. Caution with Alternatives

While repurposed drugs generate interest and anecdotal success stories, individuals should not self-medicate with unapproved or veterinary drugs. These can have serious side effects and interact unpredictably with other treatments.

4. Talk to Your Doctor

Discuss any interest in experimental or complementary approaches with a qualified oncologist or medical professional before making decisions. They can help you understand risks, potential benefits, and the latest research.

Conclusion

Colorectal cancer’s rise as a leading cause of cancer death in younger adults represents a pressing public health challenge.  Combining preventive lifestyle changes and cutting-edge research into early-onset disease could help reverse this troubling trend. 

While scientific research continues to explore biological mechanisms and potential new therapies, early diagnosis and evidence-based treatment remain vital. Repurposed antiparasitic drugs like fenbendazole and ivermectin are subjects of ongoing research and debate. Rigorous clinical trials are essential before these agents can be recommended as part of CRC treatment. 

Comments

Post a Comment

Popular posts from this blog

Ivermectin for Cancer Treatment: Protocols and Evidence (2025 Edition)

By Editorial Team
Image
Ivermectin, a drug primarily used to treat parasitic infections, has gained attention for its potential anti-cancer properties, particularly in alternative treatment protocols. Popularized by figures like Dr. William Makis, these protocols combine ivermectin with supplements and lifestyle changes to target aggressive cancers. This article explores the science, protocols, case reports, risks, and controversies surrounding ivermectin’s use in cancer treatment, providing a balanced guide for readers. What is the Ivermectin Cancer Protocol? Ivermectin cancer protocols, notably those developed by Dr. William Makis, combine ivermectin with supplements like curcumin, vitamin D, and berberine, alongside dietary and lifestyle changes. These protocols are tailored to cancer severity, with higher doses recommended for aggressive cases. The term “turbo cancers,” used by some proponents, refers to rapidly progressing cancers, though it is not a standard medical term and lacks clear scientific defin...
Read more

Exploring Ivermectin, Mebendazole and Fenbendazole as Aggressive Cancer Treatments: Research, Protocols, and Controversies (2025)

By Editorial Team
Image
Fenbendazole and ivermectin, both antiparasitic drugs that have shown potential in cancer treatment through several mechanisms, such as slowing cancer cell growth and boosting the immune response. Fenbendazole is being studied for its ability to disrupt energy production in cancer cells, effectively hindering their growth. Ivermectin, on the other hand, has been explored in combination with checkpoint inhibitors to boost the immune system's response to tumors—especially in challenging cases like triple-negative breast cancer. Introduction Cancer remains a leading cause of morbidity and mortality worldwide, with an increasing incidence of aggressive and treatment-resistant tumors such as triple-negative breast cancer (TNBC), pancreatic adenocarcinoma, and glioblastoma. Despite significant advances in targeted therapies and immunotherapies, many patients continue to face limited effective options, highlighting an urgent need for novel, affordable, and accessible treatment strategies....
Read more

Fenbendazole and Ivermectin for Cancer: A Case Series of Over 360 Patients (2026)

By Editorial Team
Image
Anecdotal reports and preliminary studies suggest that ivermectin and fenbendazole, both antiparasitic drugs, may have potential anticancer effects when used alongside other treatments.  Many people immediately dismiss the potential of ivermectin and fenbendazole when they learn it is “horse or dog medicine”. That initial reaction is overcome when genuine human success stories are told including the lack of serious side effects. The testimonials you are about to read are from individuals who have bravely shared their experiences in the hope of inspiring and uplifting others. These are raw human accounts, unfiltered by gatekeepers—not peer-reviewed studies—but they offer insights that may be valuable to those searching for options. However, we acknowledge that robust clinical trials are needed to provide more conclusive scientific evidence. Contents: Editor's Preface Introduction Fenbendazole and Ivermectin Case Series Compilation (alphabetical) Breast Cancer Success Stories  (...
Read more

Fenbendazole and the Joe Tippens Protocol: Evidence, Risks, and Current Perspective (2026 Update)

By Editorial Team
Image
Introduction The Joe Tippens Protocol revolves around the off-label use of fenbendazole (a veterinary dewormer commonly sold as Panacur C or Safe-Guard) combined with various supplements for cancer. Joe Tippens popularized this approach after claiming it contributed to his remission from metastatic small-cell lung cancer in 2017. As of 2025, Joe Tippens remains alive and reports being cancer-free for over 8 years, continuing a maintenance version of the protocol. Fenbendazole is marketed for animals (e.g., Panacur C, Safe-Guard ) and has no regulatory approval for human cancer treatment . Evidence for anticancer effects is primarily preclinical or anecdotal , and clinical trials in humans are lacking. Important Disclaimer: Fenbendazole is not approved by the FDA, EMA, or any regulatory body for human use or cancer treatment. There are no completed randomized controlled human clinical trials demonstrating its safety or efficacy against cancer. All human evidence is anecdotal, from case...
Read more

Fenbendazole vs Ivermectin for Cancer: Differences and Which Is Better?

By Editorial Team
Image
Cancer patients are increasingly inquiring about the use of the anthelmintic drugs Fenbendazole (FenBen) and Ivermectin (IVM) as potential treatments for cancer. Notably, these patients typically fall into two distinct groups, neither of which represents the usual stage 1 or 2 cancer cases where conventional therapies often show promise. The first group consists of older men whose lung or prostate cancer has recurred. Having undergone conventional treatments previously without success, they express skepticism about its effectiveness this time around. The second, larger group comprises younger patients under 40 dealing with aggressive breast cancer, colorectal cancer, or lymphoma—forms of early-onset cancers that appear to lack the typical mutations observed in traditional cases. This article aims to delve into the differences between Fenbendazole and Ivermectin by examining their me...
Read more

Top 10 Cancer Fighting Supplements: Evidence Based Literature Review (2025)

By Editorial Team
Image
Are you overwhelmed by conflicting advice on cancer, diet, and supplements ? You’re not alone. With so many claims out there, it’s hard to separate fact from fiction . Can certain foods lower your cancer risk ? Are some foods increasing it without you realizing? What about vitamin and mineral supplements —do they help prevent cancer, or could they actually increase your risk ? The term " anti-cancer supplements " can be misleading. While some nutrients support the body in cancer prevention or treatment, others may interfere with therapies or even pose risks. There are presently over 1,500 herbs and food supplements in commerce, many of them with claims in use against cancer. This guide compiles over 500 scientific r...
Read more

Fact Check: Can Ivermectin and Fenbendazole Help Treat Cancer?

By Editorial Team
Image
Ivermectin and fenbendazole, originally developed as antiparasitic drugs, are sparking hope in the fight against cancer, fueled by inspiring stories like those shared by actor  Mel Gibson on The Joe Rogan Experience , where he celebrated friends’ remarkable recoveries. While these medications aren’t yet standard cancer treatments, early research is uncovering exciting potential. Scientists are encouraged by promising lab studies and are calling for more clinical trials to confirm their effectiveness and ensure safe use in humans, paving the way for innovative, accessible therapies that could transform lives. Introduction and Context According to a January 22, 2025 fact-check article by AFP: "The anti-parasitic drugs ivermectin and fenbendazole are not currently recommended for cancer, but posts spread across social media touting the medications after actor  Mel Gibson claimed on the Joe Rogan Experience  that they cured his friends' cases of the disease. Oncology ex...
Read more

Fenbendazole and Cancer: What the Science Really Shows (Evidence, Risks & Open Questions)

By Editorial Team
Image
Abstract Background:  Fenbendazole (FBZ), a benzimidazole anthelmintic approved for veterinary use, has attracted attention for potential anticancer activity based on laboratory findings and widespread anecdotal reports.  Objective:  To critically appraise the current evidence on fenbendazole and cancer using a peer‑review style framework.  Methods:  Narrative review of preclinical studies, publicly reported human case narratives, and safety signals, with emphasis on evidence hierarchy and translational limitations.  Results:  Preclinical data demonstrate antiproliferative effects via microtubule disruption and metabolic stress in vitro and in animal models. Human evidence is limited to uncontrolled case reports; no Phase I–III clinical trials or regulatory approvals for oncology exist. Safety data in humans are sparse, with hepatotoxicity signals reported.  Conclusions:  Fenben...
Read more

Best Fenbendazole Dosage for Cancer in Humans: Benefits, Risks, and Guidelines (2025)

By Editorial Team
Image
What is Fenbendazole? Fenbendazole is a broad spectrum anti-parasitic used against gastrointestinal parasites including: giardia, roundworms, hookworms, whipworms, the tapeworm genus Taenia (but not effective against Dipylidium caninum, a common dog tapeworm), pinworms, aelurostrongylus, paragonimiasis, strongyles, and strongyloides that can be administered to sheep, cattle, horses, fish, dogs, cats, rabbits, most reptiles, freshwater shrimp tanks as planaria and hydra treatments, as well as seals. (2) Fenbendazole, has garnered ⁤attention​ for its potential use ​in‍ humans.‍ The Fenbendazole Cancer Protocol gained rapid interest over the past years following some  fenbendazole advanced cancer success stories . Joe Tippens founded the protocol  after he was told a story about a scientist at Merck Animal Health that had been performing cancer research on mice. The research included injecting different types of cancers into different mice body parts. The scientists discover...
Read more

2025 Study: Ivermectin and Balstilimab for Stage 4 Triple Negative Breast Cancer - Cedars-Sinai Medical Center Study

By Editorial Team
Image
Authors: Yuan Yuan, Jin Sun Bitar, MaLia Walker, David Lin, January Lee, So Yung Choi, Stephen Shiao, Mourad Tighiouart, Paul H. Frankel, Peter P. Lee Affiliation: Cedars-Sinai Medical Center, Los Angeles, CA Abstract e13146  (2025 ASCO Annual Meeting) is a phase 1/2 study of ivermectin in combination with balstilimab after 1-2 prior lines of therapy for triple negative breast cancer Background: Despite recent FDA approval of immune checkpoint inhibitor (ICI) and antibody-drug conjugates (ADCs), therapeutic options for metastatic triple negative breast cancer (mTNBC) remain limited. Preclinical data showed that ivermectin induces robust T cell infiltration into breast tumors and turning “cold” tumors “hot” in mouse model of TNBC. Balstilimab is a fully humanized IgG4 anti-PD-1 agent with proven safety and efficacy in metastatic cervical cancer. The current phase I/II trial is designed to test the safety and efficacy of the combination of ivermectin and balstilimab in patients wit...
Read more

Archive

Show more